Table 3 |
||
|
Final model for multivariate analysis of MFS in ER+ lymph node-negative patients1 |
||
|
Characteristic |
HR (95% CI) |
P |
|
|
||
|
Age (years) |
||
|
41-55 vs. ≤ 40 |
0.72 (0.49-1.06) |
0.101 |
|
56-70 vs. ≤ 40 |
0.43 (0.28-0.65) |
< 0.001 |
|
>70 vs. ≤ 40 |
0.44 (0.28-0.70) |
0.001 |
|
Tumor size |
||
|
pT2 vs. pT1 |
1.41 (1.07-1.84) |
0.013 |
|
pT3/4 vs. pT1 |
1.82 (0.95-3.51) |
0.073 |
|
Grade |
||
|
Good/moderate vs. Poor |
0.58 (0.38-0.87) |
0.009 |
|
Unknown vs. Poor |
1.05 (0.79-1.39) |
0.729 |
|
SIPA1 rs2448490 |
||
|
AA vs. AG+GG |
0.56 (0.38-0.85) |
0.006 |
|
RRP1B rs9306160 |
||
|
CT+TT vs. CC |
0. 71 (0.54-0.92) |
0.011 |
|
|
||
|
1761 patients CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; MFS = metastasis-free survival. |
||
|
Hsieh et al. Breast Cancer Research 2009 11:R75 doi:10.1186/bcr2412 |
||
